CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-26 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,300 | $50.17 | $266K | 113,878 |
| 2024-11-26 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $50.14 | $100K | 111,878 |
| 2024-11-26 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 5,300 | ||
| 2024-11-25 | WIERENGA WENDALL Director | Option exercise 10b5-1 | +742 | $7.37 | $5K | 25,301 |
| 2024-11-25 | WIERENGA WENDALL Director | Sale 10b5-1 | −742 | $50.00 | $37K | 24,559 |
| 2024-11-25 | WIERENGA WENDALL Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −742 | 742 | ||
| 2024-11-18 | Blum Robert I President & CEO | Option exercise 10b5-1 | +5,000 | $6.67 | $33K | 402,456 |
| 2024-11-18 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $50.55 | $253K | 397,456 |
| 2024-11-18 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 59,727 | ||
| 2024-11-12 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +5,300 | $7.96 | $42K | 120,220 |
| 2024-11-12 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,300 | $58.48 | $310K | 114,920 |
| 2024-11-12 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −1,042 | $58.48 | $61K | 113,878 |
| 2024-11-12 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 10,600 | ||
| 2024-11-01 | Blum Robert I President & CEO | Option exercise 10b5-1 | +5,000 | $6.67 | $33K | 402,456 |
| 2024-11-01 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $51.63 | $258K | 397,456 |
| 2024-11-01 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 64,727 | ||
| 2024-10-30 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +5,300 | $7.96 | $42K | 122,220 |
| 2024-10-30 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,300 | $51.90 | $275K | 116,920 |
| 2024-10-30 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $51.93 | $104K | 114,920 |
| 2024-10-30 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 15,900 |
Page 26 of 33 · 660 trades